Ten23 Health Further Develops Sterile Drug Product Manufacturing at Visp, Switzerland Location

ten23 health, a contract development and manufacturing organization (CDMO), is growing swissfillon’s manufacturing site in Visp, Switzerland. The site was acquired in October 2021 from swissfillon and will be expanded into an adjacent building with an additional 1000 square meters of cleanroom space.

The expansion will also increase the company’s cold storage and visual inspections capacity and add 10,764 square feet of cleanroom space for additional services, such as device assembly and secondary packaging, by the end of 2022. This expansion is in addition to its 43,000-plus square feet of lab and office space for its operations in Basel, Switzerland, which was launched in September 2021.

“Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland, and a testimonial of the competent and experienced team at Visp,” says Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health. “Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients.”